Abatacept/tocilizumab

  • PDF / 169,379 Bytes
  • 1 Pages / 595.245 x 841.846 pts (A4) Page_size
  • 66 Downloads / 156 Views

DOWNLOAD

REPORT


1

S

Various toxicities: 4 case reports A retrospective longitudinal study of 268 patients with rheumatoid arthritis or psoriatic arthritis, who received longterm biological therapy between 2003 and 2011 in Brazil, described four patients [ages and sexes not stated], of whom, three patients developed injection site reactions (1 patient), infection (1 patient) or immune related adverse event (1 patient) during treatment with abatacept, while the remaining one patient developed nervous system and cardiovascular side effects (1 patient) during treatment with tocilizumab [indications, routes, dosages, durations of treatments to reactions onsets and outcomes not stated] Author comment: "The most frequently reported ADRs were administration site reactions. . .infections. . .effects on nervous system". "Table 2 depicts the characteristics of the adverse events in patients taking biological agents." De Camargo MC, et al. Adverse events in patients with rheumatoid arthritis and psoriatic arthritis receiving long-term biological agents in a real-life setting. Frontiers in Pharmacology 10: 965, 2019. Available from: URL: http:// 803433862 doi.org/10.3389/fphar.2019.00965 - Brazil

0114-9954/19/1779-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved

Reactions 16 Nov 2019 No. 1779

Data Loading...